These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35300292)

  • 1. The Efficacy of Simultaneous Injection of Dexamethasone Implant and Ranibizumab Into Vitreous Cavity on Macular Edema Secondary to Central Retinal Vein Occlusion.
    Du X; Sheng Y; Shi Y; Du M; Guo Y; Li S
    Front Pharmacol; 2022; 13():842805. PubMed ID: 35300292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: a 12-month prospective study.
    Georgalas L; Tservakis I; Kiskira EE; Petrou P; Papaconstantinou D; Kanakis M
    Cutan Ocul Toxicol; 2019 Dec; 38(4):330-337. PubMed ID: 31060385
    [No Abstract]   [Full Text] [Related]  

  • 3. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
    Ozkaya A; Tarakcioglu HN; Tanir I
    Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience.
    Blanc J; Deschasse C; Kodjikian L; Dot C; Bron AM; Creuzot-Garcher C
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1441-1448. PubMed ID: 29855706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Safety and Efficacy of Intravitreal Ranibizumab with or without Laser Photocoagulation Versus Dexamethasone Intravitreal Implant with or without Laser Photocoagulation for Macular Edema Secondary to Branch Retinal Vein Occlusion.
    Kumar P; Sharma YR; Chandra P; Azad R; Meshram GG
    Folia Med (Plovdiv); 2019 Jun; 61(2):240-248. PubMed ID: 31301668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The short-term efficacy of intravitreal ranibizumab, aflibercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion.
    Yucel OE; Birinci H; Sullu Y
    Int Ophthalmol; 2019 Apr; 39(4):891-901. PubMed ID: 29550932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France.
    Korobelnik JF; Kodjikian L; Delcourt C; Gualino V; Leaback R; Pinchinat S; Velard ME
    Graefes Arch Clin Exp Ophthalmol; 2016 Dec; 254(12):2307-2318. PubMed ID: 27286894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Age and Initial Central Retinal Thickness on Earlier Need of Repeat Ozurdex Treatment for Macular Edema Due to Retinal Vein Occlusion: A Retrospective Case Series.
    Lin CJ; Chen HS; Su CW; Tien PT; Lin JM; Chen WL; Kuo CY; Lai CT; Tsai YY
    J Ocul Pharmacol Ther; 2017 Dec; 33(10):763-772. PubMed ID: 28949790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population.
    Gu X; Yu X; Song S; Dai H
    Ophthalmic Res; 2017; 58(1):8-14. PubMed ID: 28334720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study.
    Dugel PU; Capone A; Singer MA; Dreyer RF; Dodwell DG; Roth DB; Shi R; Walt JG; Scott LC; Hollander DA;
    BMC Ophthalmol; 2015 Sep; 15():118. PubMed ID: 26337664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study.
    Feltgen N; Hattenbach LO; Bertelmann T; Callizo J; Rehak M; Wolf A; Berk H; Eter N; Lang GE; Pielen A; Schmitz-Valckenberg S; Quiering C; Rose U; Hoerauf H;
    Acta Ophthalmol; 2018 Dec; 96(8):e933-e941. PubMed ID: 29855153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
    Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
    Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial.
    Eter N; Mohr A; Wachtlin J; Feltgen N; Shirlaw A; Leaback R;
    Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):77-87. PubMed ID: 27460280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.
    Haller JA; Bandello F; Belfort R; Blumenkranz MS; Gillies M; Heier J; Loewenstein A; Yoon YH; Jacques ML; Jiao J; Li XY; Whitcup SM;
    Ophthalmology; 2010 Jun; 117(6):1134-1146.e3. PubMed ID: 20417567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions.
    Pieramici DJ; Rabena M; Castellarin AA; Nasir M; See R; Norton T; Sanchez A; Risard S; Avery RL
    Ophthalmology; 2008 Oct; 115(10):e47-54. PubMed ID: 18708258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.
    Hu Q; Li H; Xu W; Du Y; Ma C; He J
    Indian J Ophthalmol; 2019 Nov; 67(11):1800-1809. PubMed ID: 31638037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.
    Haller JA; Bandello F; Belfort R; Blumenkranz MS; Gillies M; Heier J; Loewenstein A; Yoon YH; Jiao J; Li XY; Whitcup SM; ; Li J
    Ophthalmology; 2011 Dec; 118(12):2453-60. PubMed ID: 21764136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of intravitreal dexamethasone implant in patients with cataract and macular edema undergoing phacoemulsification.
    Sze AM; Luk FO; Yip TP; Lee GK; Chan CK
    Eur J Ophthalmol; 2015; 25(2):168-72. PubMed ID: 25363857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
    Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
    Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion.
    Ip MS; Gottlieb JL; Kahana A; Scott IU; Altaweel MM; Blodi BA; Gangnon RE; Puliafito CA
    Arch Ophthalmol; 2004 Aug; 122(8):1131-6. PubMed ID: 15302652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.